Welcome to our dedicated page for Pieris Pharmaceu news (Ticker: PIRS), a resource for investors and traders seeking the latest updates and insights on Pieris Pharmaceu stock.
Pieris Pharmaceuticals, Inc. (PIRS) delivers innovative biopharmaceutical solutions through its proprietary anticalin protein platform. This dedicated news hub provides investors and industry stakeholders with essential updates on clinical developments, strategic collaborations, and therapeutic advancements.
Track critical updates including clinical trial progress in immuno-oncology and respiratory therapies, partnership announcements with global pharmaceutical leaders, and regulatory milestones for novel anticalin-based treatments. Our curated news collection serves as a centralized resource for understanding PIRS's role in advancing precision-targeted therapeutics.
Discover timely updates on pipeline developments across key therapeutic areas and business strategy implementations. This repository is designed to help users monitor the company's progress in translating innovative protein engineering into clinical-stage assets.
Bookmark this page for streamlined access to Pieris Pharmaceuticals' latest announcements and scientific breakthroughs. Regularly updated to ensure you stay informed about this clinical-stage biotech innovator's evolving landscape.
Palvella Therapeutics and Pieris Pharmaceuticals have announced a definitive merger agreement to create a Nasdaq-listed, clinical-stage biopharmaceutical company. The combined entity will focus on developing novel treatments for rare genetic skin diseases, particularly QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations (LMs) and cutaneous venous malformations.
Key points:
- Expected $80.5 million in cash at closing, including $78.9 million from private financing
- Cash runway into second half of 2027
- Funding through multiple clinical trial milestones
- QTORIN™ rapamycin has FDA Breakthrough Therapy and Fast Track Designations
- Merger expected to close in Q4 2024, subject to approvals